SCHEMBL2435582

SCHEMBL2435582

COC(=O)[C@H]1CC[C@H](OC(F)(C(=O)Cc2ccc3nc(-c4cccc5ccccc45)oc3c2)N2CCCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 10/20 0.52
ITGA4 P13612 10/20 0.52
PDCD1 Q15116 2/20 0.41
CD274 Q9NZQ7 2/20 0.41
KMT2A Q03164 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HSP90AA1 P07900 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MEN1 O00255 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433631 0.92 ITGB1 (0.61) ITGB1ITGA4PDCD1CD274ESR1
SCHEMBL2432034 0.89 ITGB1 (0.53) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2439866 0.85 NPC1 (0.38) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2439864 0.85 NPC1 (0.38) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2433525 0.85 NPC1 (0.47) ITGB1ITGA4KMT2ANPC1RAB9A
SCHEMBL2432986 0.84 ITGB1 (0.55) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2437992 0.84 ITGB1 (0.56) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2437991 0.84 ITGB1 (0.56) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2432988 0.84 ITGB1 (0.55) ITGB1ITGA4PDCD1CD274KMT2A
SCHEMBL2432878 0.84 ITGB1 (0.56) ITGB1ITGA4PDCD1CD274KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ITGB1 5/4885ITGA4 4/4885PDCD1 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.